Oxford COVID-19 vaccine: Human trials expected to end by November, production from early 20212 min read . Updated: 13 Aug 2020, 07:46 PM IST
- The phase III trial has already started in United States and Brazil
- The COVID-19 vaccine has shown promising results in the first phase of clinical human trial
The phase III clinical trial of COVID-19 vaccine developed by the University of Oxford will be completed by the end of November of early December, an official said. University of Oxford joined hands with British Swedish firm Astrazeneca to make a COVID 19 vaccine. The phase III trial has already started in United States and Brazil. The vaccine has shown promising results in the first phase of clinical human trial. The researchers said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. “We are seeing good immune response in almost everybody," said Dr Adrian Hill, director of the Jenner Institute at Oxford University.
Select your Category